Hologic, Inc. $HOLX Shares Sold by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. lowered its stake in Hologic, Inc. (NASDAQ:HOLX) by 57.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 11,563 shares of the medical equipment provider’s stock after selling 15,600 shares during the quarter. Robeco Institutional Asset Management B.V.’s holdings in Hologic were worth $861,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. NewEdge Wealth LLC grew its stake in Hologic by 3.8% in the 3rd quarter. NewEdge Wealth LLC now owns 3,779 shares of the medical equipment provider’s stock valued at $281,000 after acquiring an additional 138 shares during the period. Savant Capital LLC lifted its holdings in Hologic by 0.9% in the 3rd quarter. Savant Capital LLC now owns 19,776 shares of the medical equipment provider’s stock valued at $1,335,000 after purchasing an additional 170 shares in the last quarter. UMB Bank n.a. lifted its holdings in Hologic by 38.7% in the 3rd quarter. UMB Bank n.a. now owns 620 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 173 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Hologic by 6.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 2,712 shares of the medical equipment provider’s stock valued at $183,000 after purchasing an additional 174 shares in the last quarter. Finally, OneDigital Investment Advisors LLC lifted its holdings in Hologic by 3.2% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 6,105 shares of the medical equipment provider’s stock valued at $412,000 after purchasing an additional 191 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Price Performance

NASDAQ HOLX opened at $76.01 on Friday. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $76.07. The company has a quick ratio of 3.32, a current ratio of 4.04 and a debt-to-equity ratio of 0.48. The business’s fifty day simple moving average is $75.50 and its 200-day simple moving average is $74.24. The firm has a market cap of $16.97 billion, a PE ratio of 31.67, a P/E/G ratio of 2.24 and a beta of 0.70.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the firm earned $0.87 EPS. The firm’s revenue was up 2.5% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of research reports. Argus lowered Hologic from a “buy” rating to a “hold” rating in a report on Monday, January 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a report on Wednesday, January 28th. Finally, Evercore lowered Hologic from an “outperform” rating to an “in-line” rating and decreased their price objective for the company from $79.00 to $78.00 in a report on Monday, January 5th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, Hologic currently has an average rating of “Hold” and an average price target of $78.42.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.